Statins 79 items

Studies

• Landmark REGRESS trial finds the CETP B1B1 genotype predicts who benefits from pravastatin against coronary atherosclerosis progression (N Engl J Med 1998)N Engl J Med · January 1998 9
• 13,677-subject meta-analysis confirms CETP TaqIB drives HDL and CAD risk but does not affect pravastatin response (Circulation 2005)Circulation · January 2005 9
• Network meta-analysis of 6,025 patients: obicetrapib outperforms bempedoic acid for LDL-C lowering on top of statins by 15 percentage points (J Clin Lipidol 2026)J Clin Lipidol · February 2026 8
• CETP Taq1B B2B2 genotype predicts higher cardiovascular risk despite equal statin response in familial hypercholesterolemia (Eur J Hum Genet 2005)Eur J Hum Genet · July 2005 8
• CETP TaqIB genotype fails to predict cardiovascular events or pravastatin benefit in the CARE trial cohort (J Am Coll Cardiol 2004)J Am Coll Cardiol · March 2004 8
• Plasma CETP concentration, not TaqIB genotype, predicts atherosclerosis progression and pravastatin benefit in REGRESS (Eur J Clin Invest 2004)Eur J Clin Invest · January 2004 8
• CETP -629A allele cuts cardiovascular mortality risk in half in coronary artery disease patients, independent of HDL cholesterol or CETP activity (J Am Coll Cardiol 2003)J Am Coll Cardiol · June 2003 8
• Vitamin E blocks the CETP-lowering effect of pravastatin and raises CETP concentration on its own (Coron Artery Dis 1998)Coron Artery Dis · January 1998 8
• Network meta-analysis of 9,248 patients ranks obicetrapib plus ezetimibe plus statin best overall, obicetrapib plus statin safest among CETP-inhibitor combinations (J Cardiovasc Pharmacol 2026)J Cardiovasc Pharmacol · April 2026 7
• Network meta-analysis of 33 RCTs in 120,292 adults: atorvastatin plus obicetrapib ranks best for LDL-C, rosuvastatin plus obicetrapib best for HDL-C (Clin Cardiol 2025)Clin Cardiol · September 2025 7
• The CETP locus is the only genome-wide-significant genetic determinant of HDL-C response to statins, independent of baseline HDL-C, in a 27,720-person meta-analysis (J Med Genet 2016)J Med Genet · September 2016 7
• Baseline CETP level predicts how much pitavastatin lowers LDL-C, via LXR-dependent suppression of CETP transcription (Lipids Health Dis 2016)Lipids Health Dis · March 2016 7
• CETP -629C/A genotype predicts HDL-C but the CC genotype benefits most from atorvastatin's LDL-C-lowering effect in Chinese CHD patients (Med Sci Monit 2014)Med Sci Monit · December 2014 7
• CETP enhancer variant rs3764261 boosts statin-associated HDL-C rise but reduces statin protection against myocardial infarction (Clin Pharmacol Ther 2013)Clin Pharmacol Ther · September 2013 7
• CETP and ABCA1 genotype together determine whether atorvastatin or simvastatin gives a better lipid response (Angiology 2012)Angiology · May 2012 7
• CETP TaqI and -629C/A variants predict a bigger HDL-C rise on atorvastatin, while CETP 405I/V predicts higher MI risk in CAD patients (DNA Cell Biol 2010)DNA Cell Biol · October 2010 7
• Higher on-statin CETP mass predicts fewer recurrent coronary events in the PROVE IT-TIMI 22 trial (Am J Cardiol 2010)Am J Cardiol · August 2010 7
• Genetically low CETP predicts higher 10-year mortality in statin-treated men with coronary artery disease (Eur Heart J 2008)Eur Heart J · October 2008 7
• Atorvastatin's HDL-raising effect in mice requires CETP expression, proving statins work partly by suppressing CETP (Atherosclerosis 2007)Atherosclerosis · September 2007 7
• Higher plasma CETP concentration, but not CETP genotype, predicts fewer cardiovascular events in pravastatin-treated coronary disease patients (J Intern Med 2006)J Intern Med · August 2006 7
• CETP haplotype independently predicts triglyceride response to fluvastatin in familial hypercholesterolemia (Atherosclerosis 2005)Atherosclerosis · July 2005 7
• First evidence that CETP Taq1B genotype can guide statin therapy: B2 carriers benefit strongly, B1B1 homozygotes do not (Am Heart J 2003)Am Heart J · December 2003 7
• Rosuvastatin cuts CETP mass 33-37% and, in hypertriglyceridemic patients, transfer activity by 59% (Atherosclerosis 2003)Atherosclerosis · December 2003 7
• CETP TaqIB genotype cuts cardiovascular risk 30% in non-smokers but not smokers in WOSCOPS (Eur Heart J 2003)Eur Heart J · October 2003 7
• Patients with atherogenic CETP genotypes get more HDL and triglyceride benefit from high-dose atorvastatin, DALI trial finds (Diabetes Care 2003)Diabetes Care · April 2003 7
• Higher-dose atorvastatin cuts CETP-mediated cholesteryl ester transfer 30% while boosting cholesterol efflux in type IIB hyperlipidemia (Atherosclerosis 2002)Atherosclerosis · August 2002 7
• Statins should benefit CETP TaqIB B1B1 carriers most, since they have the highest baseline CETP activity (J Atheroscler Thromb 2002)J Atheroscler Thromb · January 2002 7
• Atorvastatin preferentially reduces CETP-mediated cholesteryl ester transfer from HDL to the largest VLDL subfraction (Arterioscler Thromb Vasc Biol 2000)Arterioscler Thromb Vasc Biol · January 2000 7
• Simvastatin lowers CETP mass and activity by 16 percent in type IIb hyperlipidemia without changing CETP specific activity (Atherosclerosis 1999)Atherosclerosis · April 1999 7
• ApoE4 allele blunts the correlation between CETP activity and LDL cholesterol during colestipol and lovastatin treatment (Eur J Clin Pharmacol 1999)Eur J Clin Pharmacol · February 1999 7
• Simvastatin, unlike cholestyramine, lowers plasma CETP by 15 percent in primary hypercholesterolemia (Can J Clin Pharmacol 1999)Can J Clin Pharmacol · January 1999 7
• Pravastatin cuts CETP-mediated cholesteryl ester transfer to LDL by 24 percent in familial hypercholesterolemia without changing CETP mass (Arterioscler Thromb Vasc Biol 1995)Arterioscler Thromb Vasc Biol · September 1995 7
• Simvastatin cuts CETP activity 30 percent in type II hyperlipoproteinemia, but the change is unrelated to lipoprotein subfraction shifts (Atherosclerosis 1995)Atherosclerosis · April 1995 7
• Meta-analysis of 3,512 patients: obicetrapib added to ezetimibe nearly doubles LDL-C lowering seen with obicetrapib alone, but adds nothing to statins (Cardiol Rev 2026)Cardiol Rev · June 2026 6
• Meta-analysis of three RCTs in 3,286 patients confirms obicetrapib effects on LDL-C, apoB and HDL-C with no excess adverse events (Ann Med Surg 2026)Ann Med Surg (Lond) · June 2026 6
• Drug-drug interaction study finds no clinically meaningful effect of obicetrapib on atorvastatin or rosuvastatin exposure in healthy volunteers (Am J Cardiovasc Drugs 2025)Am J Cardiovasc Drugs · June 2025 6
• Meta-analysis of seven studies: adding a CETP inhibitor to high-intensity statins significantly raises HDL-C and lowers LDL-C with no added adverse events (Front Endocrinol 2025)Front Endocrinol (Lausanne) · January 2025 6
• CETP haplotypes predict whether lipophilic statins help or harm cognition in Alzheimer's disease (J Alzheimers Dis 2022)J Alzheimers Dis · January 2022 6
• CETP gene variants predict residual atherogenic dyslipidaemia in Thai patients on statin therapy (Pharmgenomics Pers Med 2021)Pharmgenomics Pers Med · January 2021 6
• Statin-driven normalisation of HDL lipid composition lags behind LDL and apoB reduction, revealing role of CETP (J Clin Lipidol 2018)J Clin Lipidol · January 2018 6
• CETP TaqIB B2B2 genotype blunts cholesterol-lowering response to simvastatin in Thai patients (Cardiovasc Ther 2017)Cardiovasc Ther · September 2017 6
• CETP rs708272 B2 allele is linked to a more antiatherogenic LDL subfraction profile in statin-treated coronary heart disease patients (Biochem Genet 2016)Biochem Genet · November 2016 6
• Extended-release niacin/laropiprant abolishes the postprandial rise in CETP activity and boosts HDL's fecal cholesterol removal capacity (Arterioscler Thromb Vasc Biol 2015)Arterioscler Thromb Vasc Biol · December 2015 6
• Atorvastatin fails to protect against atrial fibrillation in patients with the CETP TaqIB B2B2 genotype (J Atr Fibrillation 2015)J Atr Fibrillation · January 2015 6
• The CETP rs1532624 AA genotype has lower CETP activity, higher HDL-C, but a weaker LDL-C response to statins in Jordanian patients (Curr Mol Pharmacol 2013)Curr Mol Pharmacol · November 2013 6
• Higher CETP mass independently predicts a lower leukocyte count, and switching atorvastatin to pitavastatin raises CETP mass by 8.8 percent (Am J Cardiovasc Drugs 2012)Am J Cardiovasc Drugs · October 2012 6
• Up-titrated rosuvastatin and atorvastatin both significantly reduce CETP mass and activity in low-HDL-C cardiovascular patients (Curr Med Res Opin 2010)Curr Med Res Opin · October 2010 6
• CETP TaqIB genotype determines whether atorvastatin raises or lowers HDL cholesterol (Open Cardiovasc Med J 2010)Open Cardiovasc Med J · January 2010 6
• CETP TaqIB B2B2 genotype more than doubles cardiovascular death risk after acute coronary syndrome, unless the patient takes a statin (Clin Chem Lab Med 2009)Clin Chem Lab Med · January 2009 6
• Atorvastatin lowers CETP activity and raises paraoxonase without changing HDL cholesterol (Clin Biochem 2006)Clin Biochem · June 2006 6
• CETP B2B2 homozygotes gain over ten times more HDL cholesterol from simvastatin than B1 carriers, unlike APOE or LIPC genotypes (Clin Chim Acta 2005)Clin Chim Acta · July 2005 6
• Adding JTT-705 to pravastatin raises HDL cholesterol by 28 percent after just 4 weeks in a placebo-controlled trial (Am J Cardiol 2005)Am J Cardiol · May 2005 6
• High-dose simvastatin lowers CETP activity dose-dependently and normalizes chylomicron remnant clearance in premature CAD (Atherosclerosis 2005)Atherosclerosis · January 2005 6
• CETP gene haplotypes, not individual SNPs, are the first shown to predict lipid response to statin therapy (Pharmacogenomics J 2003)Pharmacogenomics J · January 2003 6
• Simvastatin lowers plasma CETP only in Japanese patients with elevated baseline CETP levels (Clin Chem 1998)Clin Chem · July 1998 6
• Simvastatin and cholestyramine both lower serum CETP activity in rabbits while leaving LCAT activity essentially unchanged (Cardiovasc Drugs Ther 1998)Cardiovasc Drugs Ther · March 1998 6
• Pravastatin lowers LDL and raises apoA-I but leaves CETP levels and abnormal HDL subpopulation composition unchanged (Atherosclerosis 1993)Atherosclerosis · August 1993 6
• CETP genetic variants shape the lipid response to statins in Alzheimer's disease patients (Sao Paulo Med J 2025)Sao Paulo Med J · January 2025 5
• The CETP rs708272 genotype predicts statin response only in women with hyperlipidaemia (Malays J Med Sci 2023)Malays J Med Sci · April 2023 5
• CETP genetic variants predict how much LDL cholesterol falls with statin therapy (Pharmacogenomics J 2020)Pharmacogenomics J · December 2019 5
• Niacin/laropiprant lowers CETP activity alongside multiple inflammatory markers but modestly improves HDL efflux without changing HDL antioxidant capacity (J Am Heart Assoc 2015)J Am Heart Assoc · September 2015 5
• Meta-analysis finds adding a CETP inhibitor to statin therapy does not reduce cardiovascular events (Int J Cardiol 2015)Int J Cardiol · April 2015 5
• Simvastatin blunts the boost that dalcetrapib gives to cholesterol efflux from macrophages in vitro (Cardiovasc Drugs Ther 2015)Cardiovasc Drugs Ther · February 2015 5
• The CETP locus reaches genome-wide significance for baseline Lp-PLA2 mass in a JUPITER-trial GWAS of 6,851 statin-treated participants (Circ Cardiovasc Genet 2012)Circ Cardiovasc Genet · November 2012 5
• Atorvastatin reduces exposure to dalcetrapib without diminishing its cardiovascular benefit, two crossover studies find (Expert Opin Investig Drugs 2010)Expert Opin Investig Drugs · October 2010 5
• Rosuvastatin raises its own peak concentration by 26 percent when combined with dalcetrapib, but the LDL benefit of the combination still exceeds statin alone (J Clin Pharmacol 2010)J Clin Pharmacol · May 2010 5
• Review attributes statins' modest HDL-raising effect to reduced CETP-mediated cholesterol flow (Cardiovasc Drugs Ther 2008)Cardiovasc Drugs Ther · June 2008 5
• CETP I405V I-allele carriers respond better to simvastatin, with greater triglyceride and HDL cholesterol improvement (Expert Opin Pharmacother 2007)Expert Opin Pharmacother · October 2007 5
• Review confirms CETP promoter variant -629 C to A, not TaqIB, drives CETP activity, and finds no TaqIB-pravastatin pharmacogenetic interaction (Curr Opin Lipidol 2004)Curr Opin Lipidol · August 2004 5
• Pravastatin lowers CETP activity in both fasting and postprandial states in hypercholesterolaemia (Atherosclerosis 1998)Atherosclerosis · November 1998 5
• Simvastatin lowers cholesteryl ester transfer by reducing CETP concentration itself, not by altering HDL (Atherosclerosis 1993)Atherosclerosis · March 1993 5
• In CETP mice, obicetrapib plus ezetimibe on top of atorvastatin regresses established atherosclerosis by 44% via LDL-receptor-driven VLDL clearance (J Lipid Res 2026)J Lipid Res · March 2026 4
• CETP genetic variants predict baseline LDL cholesterol but not atorvastatin response in Jordanian patients (Drug Metab Pers Ther 2022)Drug Metab Pers Ther · April 2022 4
• Baseline CETP activity nearly doubles in carriers of the eNOS T-786C polymorphism, atorvastatin crossover study finds (Arq Bras Cardiol 2013)Arq Bras Cardiol · December 2012 4
• Simvastatin lowers cholesterol in cholesterol-fed rabbits without changing CETP activity (Drug Dev Ind Pharm 2006)Drug Dev Ind Pharm · June 2006 4
• Review traces how statins raise HDL cholesterol partly via a secondary reduction in CETP activity (Curr Atheroscler Rep 2006)Curr Atheroscler Rep · January 2006 4
• Review states the once-promising CETP Taq-I to statin-response link has now been disproved (Vascul Pharmacol 2006)Vascul Pharmacol · December 2005 4
• Large pharmacogenetic screen finds CETP-HDL response to pravastatin too weak to qualify, unlike the dominant HMG-CoA reductase signal (JAMA 2004)JAMA · June 2004 4
• Atorvastatin cuts CETP activity by up to 26.4% while reshaping apolipoprotein distribution in hypertriglyceridemia (Metabolism 2000)Metabolism · February 2000 4